Novonordisk license

Moreover, we view this work as further validation and a natural extension of our technology platform. Based on what we continue to learn, this technology may play a potential role in expanding our gene editing platform toward future in vivo and ex vivo applications that can enhance our oncology pipeline," said Philip Gregory, D.

The collaboration agreement with Novo Nordisk builds upon the original research collaboration signed between bluebird bio and Novo Nordisk in , focused on identifying a development gene therapy candidate for people with hemophilia A. Novo Nordisk will be responsible for funding all research and development activities. This protein fusion architecture allows the generation of highly specific and active nucleases in a compact format compatible with all current viral and non-viral cell delivery methods.

Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.

Novo Nordisk employs about 47, people in 80 countries and markets its products in around countries. For more information, visit novonordisk. For more information, please visit www. Cancer rips time away and our goal is to work at the maximum speed of translating human thought into action — miles per hour — to give the people we serve more time.

We are building the leading immuno-oncology cell therapy company, focused on discovering new therapies and leveraging platform technologies that truly disrupt the cancer treatment landscape.

Our research and development is focused on delivering therapies that are designed with the goal to "think" smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our "why" and keeping our people and culture top of mind every day. For more information, visit www. Follow 2seventy bio on social media: Twitter and LinkedIn. No forward-looking statement can be guaranteed. We caution investors not to place considerable reliance on forward-looking statements contained in this press release.

The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, 2seventy bio undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. View source version on businesswire. Investors: Elizabeth Pingpank, elizabeth. Media: Victoria Wagner von Rinteln , victoria. Morgan Adams, morgan. CRISPR stocks will face make-or-break moments in as Big Pharma joins their quest to cure serious diseases with gene editing technology.

The pandemic accelerated a transformation Pfizer began years ago. Will Pfizer stock in continue to reflect the company's change? The omicron coronavirus symptoms you should watch out for and how to know if you have the omicron variant.

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 Following the spinout of its cancer business, bluebird bio Inc. Sources claim that when Williams' manager and close friends came to her home to check on her, she was intoxicated and belligerent and ended up being hospitalized.

In addition, BioCryst stated that it has begun enrolling patients in two pivotal clinical studies evaluating its experimental oral Factor D inhibitor, BCX, in treating rare genetic disease paroxysmal nocturnal hemoglobinuria PNH. The FDA placed a hold on the company's planned clinical trial of an experimental Alzheimer's disease drug. Bloomberg -- A divided U. Intellia Therapeutics Inc.

We will also consider the acquisition of small start-ups or parts of biotech companies in cases where there is a good match in complementary expertise and mutual interest. There are millions of people living with a serious chronic disease relying on us.

Industry leading capabilities in developing, manufacturing, and commercialising biological therapies. Sustainable and trust-based relationships, with bespoke engagement models and deal terms. Pipeline partners to develop innovative products that resolve unmet medical needs. Commercial partners to make our products accessible to patients around the world.

Contact the team.